 OCALA, Fla., April 27, 2021 GLOBE NEWSWIRE -- AIM ImmunoTech Inc. NYSE American: AIM today announced that it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events SAE. AIM also reported no SAEs in Cohort 1. The study will proceed with enrollment into Cohort 3. 